Happy #NationalSTEMDay! Century is passionate about supporting #STEM education and providing learning opportunities and mentorship to students interested in pursuing a career in STEM.
Century Therapeutics, Inc
Biotechnology
Philadelphia, Pennsylvania 22,896 followers
Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases
About us
Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites), or require potential candidates to make purchases of goods or services.
- Website
-
https://www.centurytx.com/
External link for Century Therapeutics, Inc
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
25 N 38th St
11th Floor
Philadelphia, Pennsylvania 19104, US
-
Get directions
260 Evans Way
Branchburg, New Jersey 08876, US
-
Get directions
201 Brookline Ave
Boston, Massachusetts 02215, US
Employees at Century Therapeutics, Inc
Updates
-
Today, we reported financial results and business highlights for Q3 2024. Read the press release for updates on our Phase 1 CALiPSO-1 trial of CNTY-101 in #autoimmunedisease and our Phase 1 ELiPSE-1 trial of CNTY-101 in r/r B cell #lymphomas: https://bit.ly/48yTUyB #biotech #investors
-
We are excited to announce that preclinical data from our iPSC-derived cell therapy platform will be presented in five posters at the 2024 American Society of Hematology (ASH) Annual Meeting. The posters highlight what we believe to be the first demonstration of iPSC-derived CD4+ and CD8+ CAR T cells that have αβ-like T cell function, along with preclinical data across our pipeline of iNK, γδ iT and αβ iT #celltherapy programs. Read the full release: https://bit.ly/4fdi5oy #ASH24 #ipsc
-
-
We look forward to participating in the Guggenheim Partners Inaugural Healthcare Innovation Conference. Join us on November 12 at 9:30 a.m. ET for a fireside chat featuring members of our management team. Learn more: https://bit.ly/3UDH38n
-
-
Thank you to all who joined us at Century’s 3rd Annual Gala Night to support our fundraising campaign for The Leukemia & Lymphoma Society’s #LightTheNight. We’re grateful for your contributions to advance #CancerResearch and make a positive difference for the #BloodCancer community. #Leukemia #Lymphoma #Cancelbloodcancer
-
-
This Wednesday, members of our management team will participate in a fireside chat at the William Blair CD19 Targeted Therapies in Autoimmune Diseases Conference. We look forward to sharing updates on our work to advance iPSC-derived #celltherapies for #autoimmunediseases.
-
-
We’re excited to announce the appointments of Morgan Conn, Ph.D., to Chief Financial Officer and Chad Cowan, Ph.D., to Chief Scientific Officer, effective October 14, 2024 and October 1, 2024, respectively. Morgan’s financing, business development, and corporate strategy leadership and Chad’s pioneering expertise in cell therapy will be invaluable as we continue to advance our allogeneic iPSC-derived #celltherapy platform. Learn more: https://bit.ly/3Blomjd
-
Today is #WorldCancerResearchDay. At Century, we are proud to play our part in advancing the future of #cancerresearch by developing curative cell therapies that we believe will allow us to overcome the limitations of first-generation cell therapies and expand patient access. Explore our pipeline of allogeneic, iPSC-derived NK, γδ and αβ T #celltherapy product candidates: https://bit.ly/3M5EmJw #HematologicCancers #SolidTumorCancers
-
-
Our team BBQ was the perfect way to close out the summer, with delicious food and great company. We enjoyed the opportunity to unwind, connect with each other and have some fun! #companyBBQ #teamcelebration
-
-
September is Blood Cancer Awareness Month, an opportunity to raise awareness and honor those affected by #bloodcancer. Century is proud to advance CNTY-101, which is being evaluated in the Phase 1 ELiPSE-1 trial for relapsed or refractory CD19-positive B-cell #lymphomas. #BloodCancerAwarenessMonth
-